<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Epidemiol</journal-id><journal-id journal-id-type="iso-abbrev">Am J Epidemiol</journal-id><journal-id journal-id-type="pmc-domain-id">711</journal-id><journal-id journal-id-type="pmc-domain">amjepid</journal-id><journal-id journal-id-type="publisher-id">aje</journal-id><journal-title-group><journal-title>American Journal of Epidemiology</journal-title></journal-title-group><issn pub-type="ppub">0002-9262</issn><issn pub-type="epub">1476-6256</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11879559</article-id><article-id pub-id-type="pmcid-ver">PMC11879559.1</article-id><article-id pub-id-type="pmcaid">11879559</article-id><article-id pub-id-type="pmcaiid">11879559</article-id><article-id pub-id-type="pmid">39122991</article-id><article-id pub-id-type="doi">10.1093/aje/kwae252</article-id><article-id pub-id-type="publisher-id">kwae252</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Contribution</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00860</subject></subj-group></article-categories><title-group><article-title>Abuse-deterrent formulations and opioid-related harms in North Carolina, 2010-2018</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1298-4433</contrib-id><name name-style="western"><surname>DiPrete</surname><given-names initials="BL">Bethany L</given-names></name><xref rid="cor1" ref-type="corresp"/><aff>
<institution>Department of Epidemiology, University of North Carolina at Chapel Hill</institution>, <addr-line>Chapel Hill, NC</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4098-605X</contrib-id><name name-style="western"><surname>Dasgupta</surname><given-names initials="N">Nabarun</given-names></name><aff>
<institution>Injury Prevention Research Center, University of North Carolina at Chapel Hill</institution>, <addr-line>Chapel Hill, NC</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7203-8460</contrib-id><name name-style="western"><surname>Oh</surname><given-names initials="GY">G Yeon</given-names></name><aff>
<institution>Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky</institution>, <addr-line>Lexington, KY</addr-line>, <country country="US">United States</country></aff><aff>
<institution>Institute for Pharmaceutical Outcomes &amp; Policy, College of Pharmacy, University of Kentucky</institution>, <addr-line>Lexington, KY</addr-line>, <country country="US">United States</country></aff><aff>
<institution>Sanders-Brown Center on Aging, University of Kentucky</institution>, <addr-line>Lexington, KY</addr-line>, <country country="US">United States</country></aff><aff>
<institution>Department of Epidemiology and Environmental Health, University of Kentucky</institution>, <addr-line>Lexington, KY</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3648-8197</contrib-id><name name-style="western"><surname>Moga</surname><given-names initials="DC">Daniela C</given-names></name><aff>
<institution>Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky</institution>, <addr-line>Lexington, KY</addr-line>, <country country="US">United States</country></aff><aff>
<institution>Institute for Pharmaceutical Outcomes &amp; Policy, College of Pharmacy, University of Kentucky</institution>, <addr-line>Lexington, KY</addr-line>, <country country="US">United States</country></aff><aff>
<institution>Sanders-Brown Center on Aging, University of Kentucky</institution>, <addr-line>Lexington, KY</addr-line>, <country country="US">United States</country></aff><aff>
<institution>Department of Epidemiology and Environmental Health, University of Kentucky</institution>, <addr-line>Lexington, KY</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4541-6574</contrib-id><name name-style="western"><surname>Slavova</surname><given-names initials="S">Svetla</given-names></name><aff>
<institution>Department of Biostatistics, University of Kentucky College of Public Health</institution>, <addr-line>Lexington, KY</addr-line>, United States</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Slade</surname><given-names initials="E">Emily</given-names></name><aff>
<institution>Department of Biostatistics, University of Kentucky College of Public Health</institution>, <addr-line>Lexington, KY</addr-line>, United States</aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7214-0326</contrib-id><name name-style="western"><surname>Delcher</surname><given-names initials="C">Chris</given-names></name><aff>
<institution>Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky</institution>, <addr-line>Lexington, KY</addr-line>, <country country="US">United States</country></aff><aff>
<institution>Institute for Pharmaceutical Outcomes &amp; Policy, College of Pharmacy, University of Kentucky</institution>, <addr-line>Lexington, KY</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pence</surname><given-names initials="BW">Brian W</given-names></name><aff>
<institution>Department of Epidemiology, University of North Carolina at Chapel Hill</institution>, <addr-line>Chapel Hill, NC</addr-line>, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3944-3912</contrib-id><name name-style="western"><surname>Ranapurwala</surname><given-names initials="SI">Shabbar I</given-names></name><aff>
<institution>Department of Epidemiology, University of North Carolina at Chapel Hill</institution>, <addr-line>Chapel Hill, NC</addr-line>, <country country="US">United States</country></aff><aff>
<institution>Injury Prevention Research Center, University of North Carolina at Chapel Hill</institution>, <addr-line>Chapel Hill, NC</addr-line>, <country country="US">United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1">Corresponding author: Bethany L. DiPrete, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, 135 Dauer Drive, 2101 McGavran-Greenberg Hall, Chapel Hill, NC (<email>diprete@email.unc.edu</email>)</corresp></author-notes><pub-date pub-type="collection"><month>3</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2024-08-09"><day>09</day><month>8</month><year>2024</year></pub-date><volume>194</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">483477</issue-id><fpage>680</fpage><lpage>690</lpage><history><date date-type="received"><day>31</day><month>5</month><year>2023</year></date><date date-type="rev-recd"><day>02</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>31</day><month>7</month><year>2024</year></date><date date-type="corrected-typeset"><day>18</day><month>1</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>09</day><month>08</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>05</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-06 23:25:19.233"><day>06</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="kwae252.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="kwae252.pdf"/><abstract><title>Abstract</title><p>Abuse-deterrent formulations of opioid analgesics (ADFs) were introduced to reduce opioid-related harms among pain patients, but postmarketing study results have been mixed. However, these studies may be subject to bias from selection criteria, comparator choice, and potential confounding by &#8220;indication,&#8221; highlighting the need for thorough study design considerations. In a sample of privately insured patients prescribed ADF or non-ADF extended-release/long-acting (ER/LA) opioids in North Carolina, we implemented a version of the prevalent new-user design to evaluate the relationship between ADFs and opioid use disorder (OUD, <italic toggle="yes">n</italic>&#160;=&#160;235) and opioid overdose (<italic toggle="yes">n</italic>&#160;=&#160;18) through 6 months of follow-up using inverse probability-weighted cumulative incidence functions and Fine-Gray models. The weighted hazard ratio (HR<sub>w</sub>) of opioid overdose among patients initiating ADFs was 0.87 (95% CI, 0.23-3.24) times as high as among patients who initiated, restarted, or continued non-ADF ER/LA opioids. We observed a short-term benefit of ADFs for incident OUD (HR<sub>w</sub>&#160;=&#160;0.58; 95% CI, 0.35-0.93) compared to non-ADF ER/LA opioids in the first 6 weeks of follow-up, but this benefit disappeared later in follow-up (HR<sub>w</sub>&#160;=&#160;1.30; 95% CI, 0.86-1.95). In summary, our findings add to the expanding body of evidence that there is no clear long-term reduction in harm from ADF opioids among patients in outpatient use.</p><p>
<bold>This article is part of a Special Collection on Pharmacoepidemiology</bold>.</p></abstract><kwd-group><kwd>opioid analgesics</kwd><kwd>postmarketing evaluation studies</kwd><kwd>study design</kwd><kwd>opioid prescribing</kwd><kwd>opioid-related disorder</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution content-type="funder-name">US Food and Drug Administration</institution></institution-wrap></funding-source><award-id>HHSF223201810183C</award-id></award-group></funding-group><counts><page-count count="11"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec3"><title>Introduction</title><p>Prescription opioid analgesics were commonly implicated in overdose deaths in the first 2 decades of the 2000s in the United States (abbreviations listed in <xref rid="sup1" ref-type="supplementary-material">Table S1</xref>),<xref rid="ref1" ref-type="bibr"><sup>1</sup></xref> reinvigorating pharmaceutical engineering innovations intended to reduce crushing (and injection or snorting) of tablets.<xref rid="ref2" ref-type="bibr"><sup>2</sup></xref><sup>-</sup><xref rid="ref4" ref-type="bibr"><sup>4</sup></xref> Extending back at least to the 1980s, real-world evaluations of so-called abuse-deterrent formulations (ADFs) have consistently shown mixed and limited success in reducing drug-related harms,<xref rid="ref5" ref-type="bibr"><sup>5</sup></xref><sup>-</sup><xref rid="ref13" ref-type="bibr"><sup>13</sup></xref> in part because patients prescribed the medications are somewhat distinct from those who obtain them from outside the medical system. However, starting around 2010, multiple opioid analgesic formulations were brought to market with tamper-deterring technology, including physical properties that made physical manipulation difficult or led to the release of an opioid antagonist if crushed.<xref rid="ref14" ref-type="bibr"><sup>14</sup></xref> In 2015 and 2017, the US Food and Drug Administration (FDA) provided a Guidance to Industry on the evaluation of these products, including a pathway for label claims.<xref rid="ref15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="ref16" ref-type="bibr"><sup>16</sup></xref></p><p>While premarket evaluation of new putative ADFs is well defined by these guidances, real-world evaluation has proven challenging. Surveillance and localized studies of illicit drug-using populations<xref rid="ref17" ref-type="bibr"><sup>17</sup></xref><sup>-</sup><xref rid="ref33" ref-type="bibr"><sup>33</sup></xref> have generally found meaningfully lower nonmedical use of prescription opioids with ADF properties, most of which focused on the reformulation of extended-release oxycodone (OxyContin; Purdue Pharma, LP) in the United States. A notable exception was the multimodal suite of studies conducted in Australia.<xref rid="ref34" ref-type="bibr"><sup>34</sup></xref><sup>-</sup><xref rid="ref37" ref-type="bibr"><sup>37</sup></xref> However, fewer studies have examined the impact of ADF opioids on intended patient populations with painful conditions.<xref rid="ref5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="ref38" ref-type="bibr"><sup>38</sup></xref><sup>-</sup><xref rid="ref40" ref-type="bibr"><sup>40</sup></xref></p><p>While measuring safety of ADFs in controlled trials with clear endpoints is relatively straightforward, estimating the impact of ADFs in postmarketing epidemiologic studies is more complex.<xref rid="ref41" ref-type="bibr"><sup>41</sup></xref> As highlighted by Turk et&#160;al.,<xref rid="ref41" ref-type="bibr"><sup>41</sup></xref> crucial design considerations must be accounted for in pharmacoepidemiologic studies, particularly those that utilize insurance claims data. These studies may be subject to multiple sources of bias due to selection criteria, choice of comparators, and potential confounding by &#8220;indication.&#8221;<xref rid="ref41" ref-type="bibr"><sup>41</sup></xref><sup>-</sup><xref rid="ref43" ref-type="bibr"><sup>43</sup></xref> In 2017, the FDA convened a workshop to discuss these methodological issues.<xref rid="ref44" ref-type="bibr"><sup>44</sup></xref> Most studies to date, often industry-sponsored, have focused on 1 ADF or had limited methods to address methodological difficulties.</p><p>In this study, we examined the relationship between ADFs and opioid-related harm (eg, opioid use disorder, opioid overdose) using rigorous epidemiologic methods to address issues of confounding by &#8220;indication&#8221; and choice of comparators that often arise in opioid research. We implemented a study design including patients with variable treatment histories,<xref rid="ref45" ref-type="bibr"><sup>45</sup></xref><sup>,</sup><xref rid="ref46" ref-type="bibr"><sup>46</sup></xref> comparing patients initiating ADFs to patients initiating, restarting, or continuing non-ADF extended-release/long-acting (ER/LA) opioids to understand the relationship between any ADF use and the risk of opioid-related harm.</p></sec><sec id="sec4"><title>Methods</title><sec id="sec5"><title>Data sources</title><p>Data for this analysis were from a large private health insurance provider in North Carolina (NC), United States. The data source included pharmaceutical, inpatient, and outpatient claims and membership files for individuals with (1) a pain diagnosis using the <italic toggle="yes">International Classification of Diseases, Ninth Revision, Clinical Modification</italic> (<italic toggle="yes">ICD-9-CM</italic>) and <italic toggle="yes">International Classification of Diseases, Tenth Revision, Clinical Modification</italic> (<italic toggle="yes">ICD-10-CM</italic>); (2) surgical procedure, defined using <italic toggle="yes">Current Procedural Terminology</italic> (<italic toggle="yes">CPT</italic>) codes; or (3) outpatient opioid analgesic prescription claim, identified using National Drug Codes, from January 1, 2006, through September 30, 2018. Claims data were linked to death records from the NC Department of Health and Human Services using a hierarchical matching algorithm (<xref rid="sup1" ref-type="supplementary-material">Figure S1</xref>).</p><p>This analysis was part of a larger study approved by the Institutional Review Board, Office of Human Research Ethics, University of North Carolina at Chapel Hill.</p></sec><sec id="sec6"><title>Cohort selection and study design</title><p>Adult (18-64&#160;years) patients were eligible for inclusion if they initiated ER/LA opioid analgesics (ADF or non-ADF). Patients with a documented history of opioid overdose or opioid use disorder (OUD) based on <italic toggle="yes">ICD-9-CM</italic> or <italic toggle="yes">ICD-10-CM</italic> diagnostic codes in insurance claims (<xref rid="sup1" ref-type="supplementary-material">Table S2</xref>) were excluded using all-available lookback. Lookback periods could extend before the introduction of ADF ER/LAs (hereafter referred to as &#8220;ADF&#8221;) in August 2010; however, to improve comparability between groups, we limited the analytic observation period to August 1, 2010, through September 30, 2018.</p><p>We implemented a study design similar to the prevalent new-user design<xref rid="ref45" ref-type="bibr"><sup>45</sup></xref><sup>,</sup><xref rid="ref46" ref-type="bibr"><sup>46</sup></xref> first proposed by Suissa et&#160;al<xref rid="ref45" ref-type="bibr"><sup>45</sup></xref> for examining a new drug when a standard treatment already exists, where many individuals initiating this new treatment likely have a history of exposure to the comparator treatment, as is the case with individuals initiating ADFs. This design accounts for the fact that individuals might follow different treatment trajectories when initiating the drug of interest: (1) directly switch from the comparator (ie, non-ADF ER/LA) to the drug of interest (ie, ADF), (2) switch from the comparator to the drug of interest after a treatment gap (ie, delayed switch),<xref rid="ref46" ref-type="bibr"><sup>46</sup></xref> or (3) initiate the drug of interest without prior exposure to the comparator (ie, new initiator).</p><p>This design allows us to examine our exposure of interest (ADF use) in relation to our chosen comparator (non-ADF ER/LA) through the lens of a hypothetical trial examining the following research question: &#8220;What if patients who initiated ADFs had instead initiated, continued, or re-initiated non-ADF ER/LAs at the time of ADF initiation?&#8221;<xref rid="ref46" ref-type="bibr"><sup>46</sup></xref> To examine this question, we created 2 subcohorts: ADF and non-ADF ER/LA (comparator). For the ADF subcohort, we identified individuals&#8217; first ADF outpatient pharmaceutical claim after August 1, 2010, that was not co-filled with a non-ADF ER/LA prescription on the same day (<xref rid="sup1" ref-type="supplementary-material">Figure S2</xref>). For the non-ADF ER/LA subcohort, we identified the first non-ADF ER/LA claim after August 1, 2010, for individuals who did not have a prior ADF after August 1, 2010. The ADF and non-ADF ER/LA subcohorts were not mutually exclusive; a patient could be exposed to non-ADF ER/LAs before ADF initiation but not vice versa. Individuals with claims for both an ADF and non-ADF ER/LA on the index date were excluded.</p><p>The ADF and comparator subcohorts included both traditional new users<xref rid="ref47" ref-type="bibr"><sup>47</sup></xref><sup>,</sup><xref rid="ref48" ref-type="bibr"><sup>48</sup></xref> of opioid analgesics and individuals with a history of prescription opioid use. To be considered a traditional new user, patients had to have &#8805; 6&#160;months of continuous enrollment that included a &#8805; 6-month washout period with no evidence of immediate-release (IR) or ER/LA opioid claims before ADF or non-ADF ER/LA initiation (<xref rid="sup1" ref-type="supplementary-material">Figure S2</xref>). If a patient had evidence of opioid use before ADF or non-ADF ER/LA initiation, they had to meet the 6-month continuous enrollment and washout period requirement before initiating IR or non-ADF ER/LA opioids (ADF subcohort) or IR opioids (non-ADF ER/LA subcohort). We limited analyses to the first ADF or non-ADF ER/LA initiation after July 31, 2010, that met these criteria.</p></sec><sec id="sec7"><title>Outcomes</title><p>Outcomes of interest were (1) first of: fatal opioid overdose (identified using <italic toggle="yes">ICD-10</italic> codes for underlying and contributing cause of death in linked death records, <xref rid="sup1" ref-type="supplementary-material">Table S3</xref>), or nonfatal opioid overdose; (2) diagnosed OUD; and (3) a combined outcome of first of: opioid overdose (fatal or nonfatal) or diagnosed OUD. We treated death from causes other than opioid overdose as a competing risk.<xref rid="ref49" ref-type="bibr"><sup>49</sup></xref><sup>,</sup><xref rid="ref50" ref-type="bibr"><sup>50</sup></xref></p></sec><sec id="sec8"><title>Follow-up and comparator selection</title><p>We defined the index date (baseline) as the date of ADF initiation for patients initiating ADF opioids and the date of the prescription selected as a non-ADF ER/LA comparator (<xref rid="sup1" ref-type="supplementary-material">Figures S3</xref>-<xref rid="sup1" ref-type="supplementary-material">S4</xref>).</p><p>In defining risk sets and selecting comparators, we included all new ADF prescriptions (ie, all ADF patients) and, for everyone in the ADF cohort, randomly selected 1 non-ADF ER/LA history-based comparator. To account for opioid exposure history and minimize potential selection bias from exclusion criteria in non-ADF ER/LA users with prior opioid exposure (by erroneously excluding incident opioid overdose or OUD outcomes as history events, described in detail by Suissa et&#160;al<xref rid="ref45" ref-type="bibr"><sup>45</sup></xref>), we arranged ADF index dates by calendar time and then selected 1 non-ADF ER/LA prescription (comparator) with equivalent (1) months since first non-ADF ER/LA (categorized as 0, 1-3, 4-6, 7-9, 10-12, 13-17, 18+ months and matched within &#177;2&#160;months if category spanned &gt;&#8201;4&#160;months; <xref rid="sup1" ref-type="supplementary-material">Figure S3</xref>), (2) cumulative months of non-ADF ER/LA exposure (&#177;2&#160;months), and (3) initiator type. Initiator type was categorized as new initiator, direct switch (ADF) vs continuation (non-ADF ER/LA), or delayed (&gt; 7-day gap) switch (ADF) vs reinitiation (non-ADF ER/LA),<xref rid="ref46" ref-type="bibr"><sup>46</sup></xref> accounting for IR history of no IR use (ie, traditional new user) or prevalent IR use with or without a treatment gap (<xref rid="sup1" ref-type="supplementary-material">Figure S4</xref>). If a selected control had a history of opioid overdose or OUD before the selected prescription, that individual was excluded from further control selection, and another control was selected in place of the excluded individual.<xref rid="ref45" ref-type="bibr"><sup>45</sup></xref> This process was repeated until there was 1 comparator non-ADF ER/LA prescription event for each individual in the ADF subcohort. Comparators were selected without replacement except for stratifications where a small sample size required selection with replacement.</p><p>In primary analyses, we used an approach similar to per protocol,<xref rid="ref51" ref-type="bibr"><sup>51</sup></xref> where we followed patients from baseline until the first of (1) outcome of interest, (2) death (competing risk), (3) &gt;&#8201;30&#160;days without evidence of the treatment of interest (censoring event), (4) treatment switch (censoring event), (5) disenrollment (censoring event), (6) 180&#160;days after the index date (censoring event), or (7) administrative censoring on September 30, 2018.</p></sec><sec id="sec9"><title>Patient characteristics</title><p>We identified patient characteristics relative to baseline, as defined above. Baseline patient characteristics included demographics (age, sex). We identified comorbid conditions, specifically cancer, any substance use disorder, depression, obesity, and respiratory/metabolic conditions, using Elixhauser Index code groupings<xref rid="ref52" ref-type="bibr"><sup>52</sup></xref> with a 6-month lookback. We used a derived clinical indication of acute pain, chronic pain, or surgery, identified using <italic toggle="yes">ICD-9-CM</italic> and <italic toggle="yes">ICD-10-CM</italic> codes for pain diagnoses and <italic toggle="yes">CPT</italic> codes for invasive surgery, with a 30-day lookback period to associate the derived clinical indication with the index prescription. Other prescriptions included benzodiazepines and selective serotonin reuptake inhibitors within 6&#160;months.</p><p>In contrast to previous studies, we also identified whether the ER/LA opioid prescription was concurrently prescribed with an IR opioid,<xref rid="ref53" ref-type="bibr"><sup>53</sup></xref> classifying episodes where the index prescription overlapped with an IR for &#8805; 7&#160;days (or the duration of the opioid prescription of interest if the ADF/non-ADF ER/LA episode was &lt;&#8201;7&#160;days) as concurrent. We also identified cumulative morphine milligram equivalent exposure from the first opioid prescription to the index ADF or non-ADF ER/LA prescription of interest (<xref rid="sup1" ref-type="supplementary-material">Appendix S1</xref>).<xref rid="ref53" ref-type="bibr"><sup>53</sup></xref></p></sec><sec id="sec10"><title>Statistical analysis</title><p>We used stabilized inverse probability of treatment weighting (IPTW) to account for measured confounding of the relationship between ADF use and opioid overdose or OUD. The propensity score was estimated using logistic regression to model the likelihood of treatment given measured confounders (defined in Patient characteristics, above), stratified by time since initiating non-ADF ER/LAs (in months, categorized as above) and initiator type. Confounders were identified a priori using a directed acyclic graph (<xref rid="sup1" ref-type="supplementary-material">Figure S5</xref>). We examined balance between treatment groups using standardized mean differences.<xref rid="ref54" ref-type="bibr"><sup>54</sup></xref> To account for informative censoring, we used time-varying stabilized inverse probability of censoring weights (IPCW). We multiplied IPTW by IPCW to get IPTCW, truncating weights at 0.1 and 10 to minimize the influence of extreme weights.<xref rid="ref55" ref-type="bibr"><sup>55</sup></xref></p><p>We examined the relationship between ADFs and outcomes of interest. First, we used the cumulative incidence function accounting for competing risks to estimate unweighted and weighted cumulative incidence. We used Fine-Gray<xref rid="ref56" ref-type="bibr"><sup>56</sup></xref> models to estimate unweighted and weighted hazard ratios (HR<sub>w</sub>s) with the Efron approximation for tied event times. We used Schoenfeld&#8217;s residuals to test the proportional hazards assumption and considered stratifications by time if violated. We calculated 95% confidence intervals (CIs) using robust standard errors to account for clustered observations.</p></sec><sec id="sec11"><title>Sensitivity analyses</title><p>We conducted several sensitivity analyses to evaluate the impact of analytic decisions. First, we used an approach similar to intent to treat (ITT),<xref rid="ref51" ref-type="bibr"><sup>51</sup></xref><sup>,</sup><xref rid="ref57" ref-type="bibr"><sup>57</sup></xref> where patients were followed until the first of (1) outcome, (2) death (competing risk), (3) disenrollment (censoring event), (4) 180&#160;days after the index date (censoring event), or (5) administrative censoring.</p><p>Next, we examined the relationship between ADFs and the combined outcome of opioid overdose or incident OUD diagnosis among the subset of individuals identified as new initiators of ADFs or non-ADF ER/LAs without prior IR opioid exposure (ie, traditional new users of opioids; <xref rid="sup1" ref-type="supplementary-material">Figure S4</xref>). By restricting the patient population to new initiators only, this sensitivity analysis is an example of using strict inclusion criteria to examine a single treatment strategy, comparing initiation of ADFs to initiation of non-ADF ER/LAs among individuals without a history of opioid exposure.</p><p>Finally, given that OUD is notoriously difficult to accurately measure in claims data,<xref rid="ref58" ref-type="bibr"><sup>58</sup></xref> we conducted 2 sensitivity analyses to examine the impact of OUD misclassification. First, we excluded OUD outcomes occurring in the first 30&#160;days of follow-up, assuming that these may not have been incident OUD outcomes. Second, we included medications for OUD (MOUD) in our definition of OUD (<xref rid="sup1" ref-type="supplementary-material">Table S4</xref>), excluding individuals with a history of OUD using this new definition and including additional OUD events after index based on diagnosed OUD or initiation of MOUD.</p><p>Data management was completed in SAS 9.4 (SAS Institute), and analyses were conducted in R 3.6.0 (packages listed in <xref rid="sup1" ref-type="supplementary-material">Table S5</xref>).<xref rid="ref59" ref-type="bibr"><sup>59</sup></xref></p></sec></sec><sec id="sec12"><title>Results</title><sec id="sec13"><title>Patient characteristics</title><p>We identified 7969 patients initiating ADFs, of whom 2260 (28.4%) were classified as traditional new users, and 5709 (71.6%) were classified as patients with prior opioid exposure (<xref rid="TB1" ref-type="table">Table 1</xref>). For the group of patients to serve as comparators, we identified 8888 patients initiating non-ADF ER/LAs contributing 48&#8201;797 observations used for the selection of 7969 comparator observations to match exposure histories of ADF patients (defined in Comparator selection, above).</p><table-wrap position="float" id="TB1" orientation="portrait"><label>Table 1</label><caption><p>Opioid treatment history of individuals initiating ADFs or initiating, reinitiating, or continuing ER/LA opioids enrolled in private health insurance from a large provider in North Carolina, 2010-2018.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">&#160;</th><th align="left" rowspan="1" colspan="1">
<bold>Non-ADF ER/LA</bold> &#160;<break/><bold><italic toggle="yes">n</italic>&#160;=&#160;7969</bold></th><th align="left" rowspan="1" colspan="1">
<bold>ADF ER/LA</bold> &#160;<break/><bold><italic toggle="yes">n</italic>&#160;=&#160;7969</bold></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Traditional new user (&gt; 6&#160;months with no opioid claims)</td><td align="left" rowspan="1" colspan="1">2260 (28.36)</td><td align="left" rowspan="1" colspan="1">2260 (28.36)</td></tr><tr><td align="left" colspan="3" rowspan="1">Concurrent IR</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No concurrent IR</td><td align="left" rowspan="1" colspan="1">1431 (63.32)</td><td align="left" rowspan="1" colspan="1">1431 (63.32)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Concurrent IR</td><td align="left" rowspan="1" colspan="1">829 (36.68)</td><td align="left" rowspan="1" colspan="1">829 (36.68)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prior opioid exposure (&#8804; 6&#160;months since last opioid claim)</td><td align="left" rowspan="1" colspan="1">5709 (71.64)</td><td align="left" rowspan="1" colspan="1">5709 (71.64)</td></tr><tr><td align="left" colspan="3" rowspan="1">Switch</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Direct switch from ER/LA</td><td align="left" rowspan="1" colspan="1">426 (7.46)</td><td align="left" rowspan="1" colspan="1">426 (7.46)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Direct switch from IR</td><td align="left" rowspan="1" colspan="1">3429 (60.06)</td><td align="left" rowspan="1" colspan="1">3429 (60.06)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Delayed switch from ER/LA</td><td align="left" rowspan="1" colspan="1">161 (2.82)</td><td align="left" rowspan="1" colspan="1">161 (2.82)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Delayed switch from IR</td><td align="left" rowspan="1" colspan="1">1693 (29.65)</td><td align="left" rowspan="1" colspan="1">1693 (29.65)</td></tr><tr><td align="left" colspan="3" rowspan="1">Opioid treatment history</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;ER/LA and IR</td><td align="left" rowspan="1" colspan="1">894 (15.66)</td><td align="left" rowspan="1" colspan="1">894 (15.66)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;ER/LA only</td><td align="left" rowspan="1" colspan="1">20 (0.35)</td><td align="left" rowspan="1" colspan="1">20 (0.35)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;IR only</td><td align="left" rowspan="1" colspan="1">4795 (83.99)</td><td align="left" rowspan="1" colspan="1">4795 (83.99)</td></tr><tr><td align="left" colspan="3" rowspan="1">Concurrent IR</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No concurrent IR</td><td align="left" rowspan="1" colspan="1">2711 (47.49)</td><td align="left" rowspan="1" colspan="1">2711 (47.49)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Concurrent IR</td><td align="left" rowspan="1" colspan="1">2998 (52.51)</td><td align="left" rowspan="1" colspan="1">2998 (52.51)</td></tr><tr><td align="left" colspan="3" rowspan="1">&#8195;Months since first ER/LA</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;0</td><td align="left" rowspan="1" colspan="1">4874 (85.37)</td><td align="left" rowspan="1" colspan="1">4874 (85.37)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;1-3</td><td align="left" rowspan="1" colspan="1">216 (3.78)</td><td align="left" rowspan="1" colspan="1">216 (3.78)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;4-6</td><td align="left" rowspan="1" colspan="1">114 (2)</td><td align="left" rowspan="1" colspan="1">114 (2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;7-9</td><td align="left" rowspan="1" colspan="1">79 (1.38)</td><td align="left" rowspan="1" colspan="1">79 (1.38)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;10-12</td><td align="left" rowspan="1" colspan="1">70 (1.23)</td><td align="left" rowspan="1" colspan="1">70 (1.23)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;13-17</td><td align="left" rowspan="1" colspan="1">100 (1.75)</td><td align="left" rowspan="1" colspan="1">100 (1.75)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;18+</td><td align="left" rowspan="1" colspan="1">256 (4.48)</td><td align="left" rowspan="1" colspan="1">256 (4.48)</td></tr><tr><td align="left" colspan="3" rowspan="1">Months since first opioid</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;1-3</td><td align="left" rowspan="1" colspan="1">1747 (30.6)</td><td align="left" rowspan="1" colspan="1">2178 (38.15)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;4-6</td><td align="left" rowspan="1" colspan="1">855 (14.98)</td><td align="left" rowspan="1" colspan="1">905 (15.85)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;7-9</td><td align="left" rowspan="1" colspan="1">640 (11.21)</td><td align="left" rowspan="1" colspan="1">572 (10.02)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;10-12</td><td align="left" rowspan="1" colspan="1">419 (7.34)</td><td align="left" rowspan="1" colspan="1">335 (5.87)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;13-17</td><td align="left" rowspan="1" colspan="1">503 (8.81)</td><td align="left" rowspan="1" colspan="1">406 (7.11)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;18+</td><td align="left" rowspan="1" colspan="1">1545 (27.06)</td><td align="left" rowspan="1" colspan="1">1313 (23)</td></tr><tr><td align="left" colspan="3" rowspan="1">Average daily dosage (MME)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Average MME, median (IQR)</td><td align="left" rowspan="1" colspan="1">40 (27-60)</td><td align="left" rowspan="1" colspan="1">44 (30-64)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: ADF, abuse-deterrent formulation of opioid analgesics; ER/LA, extended-release/long-acting formulations of opioid analgesics; IQR, interquartile range; IR, immediate-release formulation of opioid analgesics; MME, morphine milligram equivalent.</p></table-wrap-foot></table-wrap><p>The median age at baseline was similar between the ADF (51&#160;years; interquartile range [IQR], 41-57) and non-ADF ER/LA groups (50&#160;years; IQR, 41-57) (<xref rid="TB2" ref-type="table">Table 2</xref>). ADF initiators were less likely to be female (45.2% vs 49.6%) and were less likely to have received benzodiazepines (31.2% vs 34.8%) within 6&#160;months before baseline. However, patients initiating an ADF were more likely to have had recent invasive surgery (42.1% vs 14.0%), an acute pain diagnosis (41.4% vs 24.5%), or a chronic pain diagnosis (80.1% vs 71.4%). Patients initiating an ADF were also less likely to have several baseline comorbidities, including depression (19.8% vs 22.1%), metastatic cancer (10.6% vs 13.3%), or solid tumor without metastasis (15.3% vs 19.1%) but were more likely to have obesity (14.4% vs 12.1%). Covariates were well balanced after implementing IPTW (<xref rid="sup1" ref-type="supplementary-material">Figure S6</xref>).</p><table-wrap position="float" id="TB2" orientation="portrait"><label>Table 2</label><caption><p>Baseline characteristics of individuals initiating ADFs or initiating, reinitiating, or continuing ER/LA opioids enrolled in private health insurance from a large provider in North Carolina, 2010-2018.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">&#160;</th><th align="left" rowspan="1" colspan="1">
<bold>Non-ADF ER/LA</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>ADF ER/LA</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</td><td align="left" rowspan="1" colspan="1">7969</td><td align="left" rowspan="1" colspan="1">7969</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, median [IQR], y</td><td align="left" rowspan="1" colspan="1">50 [41, 57]</td><td align="left" rowspan="1" colspan="1">51 [41, 57]</td></tr><tr><td align="left" rowspan="1" colspan="1">Female, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">3954 (49.6)</td><td align="left" rowspan="1" colspan="1">3600 (45.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Index year, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2010</td><td align="left" rowspan="1" colspan="1">701 (8.8)</td><td align="left" rowspan="1" colspan="1">440 (5.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2011</td><td align="left" rowspan="1" colspan="1">1166 (14.6)</td><td align="left" rowspan="1" colspan="1">1090 (13.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2012</td><td align="left" rowspan="1" colspan="1">1162 (14.6)</td><td align="left" rowspan="1" colspan="1">1083 (13.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2013</td><td align="left" rowspan="1" colspan="1">1053 (13.2)</td><td align="left" rowspan="1" colspan="1">1143 (14.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2014</td><td align="left" rowspan="1" colspan="1">1125 (14.1)</td><td align="left" rowspan="1" colspan="1">1191 (14.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2015</td><td align="left" rowspan="1" colspan="1">1109 (13.9)</td><td align="left" rowspan="1" colspan="1">1228 (15.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2016</td><td align="left" rowspan="1" colspan="1">784 (9.8)</td><td align="left" rowspan="1" colspan="1">924 (11.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2017</td><td align="left" rowspan="1" colspan="1">635 (8.0)</td><td align="left" rowspan="1" colspan="1">652 (8.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;2018</td><td align="left" rowspan="1" colspan="1">234 (2.9)</td><td align="left" rowspan="1" colspan="1">218 (2.7)</td></tr><tr><td align="left" colspan="3" rowspan="1">Other medications, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Benzodiazepines</td><td align="left" rowspan="1" colspan="1">2773 (34.8)</td><td align="left" rowspan="1" colspan="1">2486 (31.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;SSRIs</td><td align="left" rowspan="1" colspan="1">1501 (18.8)</td><td align="left" rowspan="1" colspan="1">1462 (18.3)</td></tr><tr><td align="left" colspan="3" rowspan="1">Pain/surgery, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Surgery</td><td align="left" rowspan="1" colspan="1">1114 (14.0)</td><td align="left" rowspan="1" colspan="1">3356 (42.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Acute pain</td><td align="left" rowspan="1" colspan="1">1950 (24.5)</td><td align="left" rowspan="1" colspan="1">3303 (41.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Chronic pain</td><td align="left" rowspan="1" colspan="1">5692 (71.4)</td><td align="left" rowspan="1" colspan="1">6382 (80.1)</td></tr><tr><td align="left" colspan="3" rowspan="1">Elixhauser comorbidity, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Congestive heart failure</td><td align="left" rowspan="1" colspan="1">213 (2.7)</td><td align="left" rowspan="1" colspan="1">191 (2.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Cardiac arrhythmia</td><td align="left" rowspan="1" colspan="1">822 (10.3)</td><td align="left" rowspan="1" colspan="1">806 (10.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Valvular disease</td><td align="left" rowspan="1" colspan="1">308 (3.9)</td><td align="left" rowspan="1" colspan="1">252 (3.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Pulmonary circulation disorders</td><td align="left" rowspan="1" colspan="1">161 (2.0)</td><td align="left" rowspan="1" colspan="1">173 (2.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Peripheral vascular disorders</td><td align="left" rowspan="1" colspan="1">336 (4.2)</td><td align="left" rowspan="1" colspan="1">297 (3.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Hypertension uncomplicated</td><td align="left" rowspan="1" colspan="1">2924 (36.7)</td><td align="left" rowspan="1" colspan="1">3020 (37.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Hypertension complicated</td><td align="left" rowspan="1" colspan="1">260 (3.3)</td><td align="left" rowspan="1" colspan="1">296 (3.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Paralysis</td><td align="left" rowspan="1" colspan="1">92 (1.2)</td><td align="left" rowspan="1" colspan="1">75 (0.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Other neurological disorders</td><td align="left" rowspan="1" colspan="1">327 (4.1)</td><td align="left" rowspan="1" colspan="1">258 (3.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Chronic pulmonary disease</td><td align="left" rowspan="1" colspan="1">1139 (14.3)</td><td align="left" rowspan="1" colspan="1">975 (12.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Diabetes uncomplicated</td><td align="left" rowspan="1" colspan="1">1115 (14.0)</td><td align="left" rowspan="1" colspan="1">1006 (12.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Diabetes complicated</td><td align="left" rowspan="1" colspan="1">346 (4.3)</td><td align="left" rowspan="1" colspan="1">317 (4.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Hypothyroidism</td><td align="left" rowspan="1" colspan="1">837 (10.5)</td><td align="left" rowspan="1" colspan="1">759 (9.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Renal failure</td><td align="left" rowspan="1" colspan="1">280 (3.5)</td><td align="left" rowspan="1" colspan="1">234 (2.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Liver disease</td><td align="left" rowspan="1" colspan="1">676 (8.5)</td><td align="left" rowspan="1" colspan="1">623 (7.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Peptic ulcer disease excluding bleeding</td><td align="left" rowspan="1" colspan="1">85 (1.1)</td><td align="left" rowspan="1" colspan="1">86 (1.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;AIDS/HIV</td><td align="left" rowspan="1" colspan="1">17 (0.2)</td><td align="left" rowspan="1" colspan="1">14 (0.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Lymphoma</td><td align="left" rowspan="1" colspan="1">153 (1.9)</td><td align="left" rowspan="1" colspan="1">156 (2.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Metastatic cancer</td><td align="left" rowspan="1" colspan="1">1060 (13.3)</td><td align="left" rowspan="1" colspan="1">841 (10.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Solid tumor without metastasis</td><td align="left" rowspan="1" colspan="1">1520 (19.1)</td><td align="left" rowspan="1" colspan="1">1221 (15.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Rheumatoid arthritis/collagen</td><td align="left" rowspan="1" colspan="1">729 (9.1)</td><td align="left" rowspan="1" colspan="1">502 (6.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Coagulopathy</td><td align="left" rowspan="1" colspan="1">313 (3.9)</td><td align="left" rowspan="1" colspan="1">295 (3.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Obesity</td><td align="left" rowspan="1" colspan="1">967 (12.1)</td><td align="left" rowspan="1" colspan="1">1149 (14.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Weight loss</td><td align="left" rowspan="1" colspan="1">543 (6.8)</td><td align="left" rowspan="1" colspan="1">413 (5.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Fluid and electrolyte disorders</td><td align="left" rowspan="1" colspan="1">1055 (13.2)</td><td align="left" rowspan="1" colspan="1">913 (11.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Blood loss anemia</td><td align="left" rowspan="1" colspan="1">84 (1.1)</td><td align="left" rowspan="1" colspan="1">92 (1.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Deficiency anemia</td><td align="left" rowspan="1" colspan="1">347 (4.4)</td><td align="left" rowspan="1" colspan="1">316 (4.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Alcohol use disorder</td><td align="left" rowspan="1" colspan="1">264 (3.3)</td><td align="left" rowspan="1" colspan="1">269 (3.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Substance use disorder</td><td align="left" rowspan="1" colspan="1">274 (3.4)</td><td align="left" rowspan="1" colspan="1">203 (2.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Psychoses</td><td align="left" rowspan="1" colspan="1">78 (1.0)</td><td align="left" rowspan="1" colspan="1">74 (0.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Depression</td><td align="left" rowspan="1" colspan="1">1763 (22.1)</td><td align="left" rowspan="1" colspan="1">1581 (19.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Total Elixhauser groups, median [IQR]</td><td align="left" rowspan="1" colspan="1">2 [1, 4]</td><td align="left" rowspan="1" colspan="1">2 [0, 3]</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: ADF, abuse-deterrent formulation of opioid analgesics; ER/LA, extended-release/long-acting formulations of opioid analgesics; IQR, interquartile range; SSRI, selective serotonin reuptake inhibitor.</p></table-wrap-foot></table-wrap></sec><sec id="sec14"><title>Follow-up and events</title><p>In our primary analysis, patients were followed for a median of 60&#160;days (IQR, 40-178&#160;days; <xref rid="sup1" ref-type="supplementary-material">Table S6</xref>), with non-ADF ER/LA patients contributing more follow-up (median 74&#160;days; IQR, 52-182) than ADF initiators (median 50&#160;days; IQR, 39-115&#160;days) due to a higher proportion of ADF patients being censored for treatment switching and/or&#160;&gt;&#160;30&#160;days without ADFs (per-protocol censoring). Across all observations, there were 18 fatal or nonfatal opioid overdoses (ADF: <italic toggle="yes">n</italic>&#160;=&#160;8, non-ADF ER/LA: <italic toggle="yes">n</italic>&#160;=&#160;10) and 235 incident OUD diagnoses (ADF: <italic toggle="yes">n</italic>&#160;=&#160;91, non-ADF ER/LA: <italic toggle="yes">n</italic>&#160;=&#160;144). A competing risk of death occurred for 4% of observations in each outcome analysis.</p></sec><sec id="sec15"><title>Model results</title><p>Cumulative incidence of opioid overdose was consistently higher among patients who initiated, restarted, or continued non-ADF ER/LAs through the first 3 months of follow-up compared to patients who initiated ADFs in both crude (<xref rid="sup1" ref-type="supplementary-material">Figure S7a</xref>) and IPTCW (<xref rid="f1" ref-type="fig">Figure 1A</xref>) analyses, although with considerable confidence interval overlap. Similarly, cumulative incidence of OUD was consistently higher through the first 3 months of follow-up among patients who initiated, restarted, or continued non-ADF ER/LAs compared to patients who initiated ADFs in both crude (<xref rid="sup1" ref-type="supplementary-material">Figure S7b</xref>) and IPTCW (<xref rid="f1" ref-type="fig">Figure 1B</xref>) analyses, with the curves converging later in follow-up. Interestingly, the separation between the cumulative incidence curves is much greater in the first 6&#160;weeks of follow-up compared to 7&#160;weeks and later, particularly after weighting to account for confounding and informative censoring.</p><fig position="float" id="f1" orientation="portrait"><label>Figure 1</label><caption><p>Inverse probability-weighted cumulative incidence of (A) nonfatal or fatal opioid overdose, (B) OUD, and (C) combined outcome of OUD or opioid overdose. Among individuals initiating ADF ER/LAs (red) compared to those initiating, reinitiating, or continuing non-ADF ER/LA (blue) opioids in North Carolina, 2010-2018, using an approach similar to per-protocol. ADF, abuse-deterrent formulation of opioid analgesics; ER/LA, extended-release/long-acting formulations of opioid analgesics; OUD, opioid use disorder.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="kwae252f1.jpg"/></fig><p>In Fine-Gray models of opioid overdose outcomes (<xref rid="f2" ref-type="fig">Figure 2</xref>, <xref rid="sup1" ref-type="supplementary-material">Table S7</xref>), the weighted hazard of nonfatal or fatal opioid overdose among patients initiating ADFs was 0.87 (95% CI, 0.23-3.24) times as high as the hazard among patients who initiated, restarted, or continued non-ADF ER/LAs, respectively. Tests indicated that the proportional hazards assumption for OUD outcome models was not upheld, suggesting the need to report separate estimates for the first 6&#160;weeks of follow-up vs the remainder of follow-up. Among patients initiating ADFs, the weighted hazard of incident OUD was 0.58 (95% CI, 0.35-0.93) times as high as among patients who initiated, restarted, or continued non-ADF ER/LAs in the first 6&#160;weeks of follow-up and 1.30 (95% CI, 0.86-1.95) times as high through the rest of follow-up (<xref rid="sup1" ref-type="supplementary-material">Table S8</xref>). We observed a similar relationship for the combined outcome of OUD or opioid overdose.</p><fig position="float" id="f2" orientation="portrait"><label>Figure 2</label><caption><p>Inverse probability-weighted hazard ratios for nonfatal or fatal opioid overdose (blue), opioid use disorder (orange), and combined outcome of opioid use disorder or opioid overdose (green). Comparing individuals initiating ADF ER/LAs to those initiating, reinitiating, or continuing non-ADF ER/LA opioids in North Carolina, 2010-2018, using ITT (left) and per-protocol (right) approaches. ADF, abuse-deterrent formulation of opioid analgesics; ER/LA, extended-release/long-acting formulations of opioid analgesics; HR, hazard ratio; ITT, intent to treat; OUD, opioid use disorder.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="kwae252f2.jpg"/></fig></sec><sec id="sec16"><title>Sensitivity analyses</title><p>In the first sensitivity analysis using an ITT approach, patients were followed for a median of 6&#160;months, and there were 29 fatal or nonfatal opioid overdoses and 347 incident OUD diagnoses (<xref rid="sup1" ref-type="supplementary-material">Table S9</xref>). In this ITT analysis, we again found that the cumulative incidence of opioid overdose was consistently higher among patients who initiated, restarted, or continued non-ADF ER/LAs compared to patients who initiated ADFs through the first 3 months of follow-up (although with considerable CI overlap), with curves converging later in follow-up (<xref rid="f3" ref-type="fig">Figure 3A</xref>, <xref rid="sup1" ref-type="supplementary-material">Figure S8</xref>). We also observed a similar relationship for OUD outcomes between the per-protocol and ITT analyses, with the greatest separation between cumulative incidence curves occurring early in follow-up (<xref rid="f3" ref-type="fig">Figure 3B, C</xref>). In regression models, the weighted hazard of opioid overdose among patients initiating ADFs was 1.29 (95% CI, 0.46-3.58) times as high as among patients who initiated, restarted, or continued non-ADF ER/LAs (<xref rid="f2" ref-type="fig">Figure 2</xref>, <xref rid="sup1" ref-type="supplementary-material">Table S7</xref>). Further, the weighted hazard of incident OUD was 0.55 (95% CI, 0.34-0.90) times as high as among patients who initiated, restarted, or continued non-ADF ER/LAs in the first 6&#160;weeks of follow-up and 1.10 (95% CI, 0.79-1.53) times as high through the remainder of follow-up (<xref rid="f2" ref-type="fig">Figure 2</xref>, <xref rid="sup1" ref-type="supplementary-material">Table S8</xref>).</p><fig position="float" id="f3" orientation="portrait"><label>Figure 3</label><caption><p>Inverse probability-weighted cumulative incidence of (A) nonfatal or fatal opioid overdose, (B) OUD, and (C) combined outcome of OUD or opioid overdose. Among individuals initiating ADF ER/LAs (red) compared to those initiating, reinitiating, or continuing non-ADF ER/LA (blue) opioids in North Carolina, 2010-2018, using an approach similar to intent to treat. ADF, abuse-deterrent formulation of opioid analgesics; ER/LA, extended-release/long-acting formulations of opioid analgesics; OUD, opioid use disorder.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="kwae252f3.jpg"/></fig><p>Second, we restricted our analysis to patients who met the criteria of traditional new users (<italic toggle="yes">n</italic>&#160;=&#160;4520) and examined the combined outcome of opioid overdose or OUD. In this subcohort, there were 39 and 45 events within 6 months of follow-up using per-protocol and ITT approaches, respectively. We found that ADFs were associated with a lower risk of opioid overdose or OUD through 6 months of follow-up using both per-protocol (HR<sub>w</sub>&#160;=&#160;0.37; 95% CI, 0.14-1.01; <xref rid="sup1" ref-type="supplementary-material">Figures S9</xref>-<xref rid="sup1" ref-type="supplementary-material">S10</xref>) and ITT approaches (HR<sub>w</sub>&#160;=&#160;0.44; 95% CI, 0.19-1.01; <xref rid="sup1" ref-type="supplementary-material">Figures S11</xref>-<xref rid="sup1" ref-type="supplementary-material">S12</xref>).</p><p>Third, there were 62 OUD events (ADF subcohort: <italic toggle="yes">n</italic>&#160;=&#160;28) occurring in the first 30&#160;days of follow-up and 58 OUD events (ADF subcohort: <italic toggle="yes">n</italic>&#160;=&#160;27) occurring in the first 30&#160;days when considering the combined outcome of OUD and opioid overdose, which were excluded from the analytic cohort for this sensitivity analysis. In this restricted subcohort, there were 173 incident OUD diagnoses (<xref rid="sup1" ref-type="supplementary-material">Tables S10</xref>-<xref rid="sup1" ref-type="supplementary-material">S11</xref>).</p><p>In the final sensitivity analysis including MOUD in the definition of OUD, there were 23 individuals who had evidence of MOUD (ADF: <italic toggle="yes">n</italic>&#160;=&#160;6, non-ADF ER/LA: <italic toggle="yes">n</italic>&#160;=&#160;17) before cohort entry and were thus excluded from the analytic cohort for this sensitivity analysis. In this subcohort restricted to individuals without evidence of MOUD before cohort entry, there were 237 incident OUD diagnoses or initiation of MOUD (<xref rid="sup1" ref-type="supplementary-material">Tables S10</xref>-<xref rid="sup1" ref-type="supplementary-material">S11</xref>). Results from these sensitivity analyses were consistent with results from primary analyses (<xref rid="sup1" ref-type="supplementary-material">Figures S13</xref>-<xref rid="sup1" ref-type="supplementary-material">S15</xref>).</p></sec></sec><sec id="sec17"><title>Discussion</title><p>In this large cohort of patients exposed to ER/LA opioids from 2010 through 2018 in NC, we examined the incidence of fatal or nonfatal opioid overdoses and diagnosed OUD, comparing patients who initiated ADFs to patients initiating, restarting, or continuing non-ADF ER/LA opioids. While the cumulative incidence of opioid overdose was lower in the ADF subcohort through the first 3 months of follow-up, there was considerable confidence interval overlap. Further, there was no notable relationship between ADF use and opioid overdose through 6 months of follow-up in regression models. We additionally found that ADF use was associated with a lower risk of OUD early in follow-up. Interestingly, while the hazard of OUD was significantly lower for patients prescribed ADFs compared to patients prescribed non-ADF ER/LAs for the first 6 weeks of follow-up, the direction of this relationship changed later in follow-up, with the hazard of OUD higher 7&#160;weeks through 6&#160;months among patients exposed to ADFs compared to non-ADF ER/LAs.</p><p>Several studies have sought to address whether the introduction of ADFs, which tend to be more expensive than non-ADF ER/LA opioids,<xref rid="ref60" ref-type="bibr"><sup>60</sup></xref> was effective in reducing opioid-related harms using varied study designs,<xref rid="ref42" ref-type="bibr"><sup>42</sup></xref> but this growing body of evidence has yielded mixed results.<xref rid="ref17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="ref18" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="ref20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="ref30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="ref61" ref-type="bibr"><sup>61</sup></xref><sup>-</sup><xref rid="ref65" ref-type="bibr"><sup>65</sup></xref> Our findings are consistent with 1 large study on OxyContin reformulation<xref rid="ref40" ref-type="bibr"><sup>40</sup></xref> commissioned by the manufacturer using Medicaid and commercial claims data. That study found no meaningful difference in overdose rates in general but noted somewhat lower overdose among patients not taking other opioid medications concurrently. However, 78% of patients receiving ER/LA opioids are also prescribed IR opioids,<xref rid="ref53" ref-type="bibr"><sup>53</sup></xref> limiting interpretation. The other large study on this topic,<xref rid="ref5" ref-type="bibr"><sup>5</sup></xref> which used electronic health records, found increased overdose and OUD diagnoses in the ADF oxycodone cohort but only used IR oxycodone as the comparison group.<xref rid="ref66" ref-type="bibr"><sup>66</sup></xref> A study of an ADF morphine product<xref rid="ref38" ref-type="bibr"><sup>38</sup></xref> in Medicaid found higher overdose and OUD diagnoses in the non-ADF ER/LA group but had no adjustment for confounding. Given the complexity of evaluating ADFs in a postmarketing setting, there have been multiple calls to critically evaluate and improve upon the methods used to conduct postmarketing surveillance studies of ADFs.<xref rid="ref15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="ref41" ref-type="bibr"><sup>41</sup></xref><sup>,</sup><xref rid="ref42" ref-type="bibr"><sup>42</sup></xref><sup>,</sup><xref rid="ref67" ref-type="bibr"><sup>67</sup></xref></p><p>When designing observational postmarketing studies, key considerations include the choice of study design, appropriate comparators, accounting for confounding by &#8220;indication,&#8221; and selection bias.<xref rid="ref41" ref-type="bibr"><sup>41</sup></xref><sup>,</sup><xref rid="ref42" ref-type="bibr"><sup>42</sup></xref><sup>,</sup><xref rid="ref58" ref-type="bibr"><sup>58</sup></xref><sup>,</sup><xref rid="ref67" ref-type="bibr"><sup>67</sup></xref> Many of these studies examined only a single ADF formulation instead of all ADFs as a class, thereby limiting generalizability. These choices influence the reliability of conclusions that can be drawn from observational studies.<xref rid="ref66" ref-type="bibr"><sup>66</sup></xref> Our goal in this study was to implement a methodologically rigorous approach to estimate the relationship between ADFs and opioid-related harms in a population of patients we believed to be representative of the general clinical population of patients who are prescribed ADF opioids while accounting for confounding by &#8220;indication&#8221; through comparator selection and propensity score&#8211;based methods. In primary analyses, our finding of no clear relationship between ADF use and opioid overdose and a short-term reduction in risk of OUD compared to non-ADF ER/LAs was supported by multiple sensitivity analyses and is consistent with much of the growing evidence base.</p><p>Our primary analysis combined patient populations with heterogeneous treatment histories, including those who had no history of exposure to opioid analgesics, patients who had prior IR opioid exposure but no non-ADF ER/LA exposure, and patients with prior non-ADF ER/LA use. This approach allows us to examine the relationship between ADF exposure and opioid-related harms in varying treatment strategies that attempt to more closely capture real-world prescribing trajectories: (1) directly switch from the comparator (ie, non-ADF ER/LA) to the drug of interest (ie, ADF), (2) switch from the comparator to the drug of interest after a treatment gap (ie, delayed switch), or (3) initiate the drug of interest without prior exposure to the comparator (ie, new initiator).<xref rid="ref46" ref-type="bibr"><sup>46</sup></xref> However, combining these different patient populations adds analytic complexity due to different anticipated confounding structures given heterogeneous treatment histories. We attempt to address this complexity in our weighting strategy by modeling the probability of initiating ADFs stratified by treatment history.<xref rid="ref46" ref-type="bibr"><sup>46</sup></xref> Our sensitivity analysis restricting the population to patients without prior opioid exposure is an example of an analysis that utilizes a narrow, explicit set of inclusion criteria to examine a single treatment comparison: initiation of ADFs vs non-ADF ER/LAs among patients without prior opioid exposure. This sensitivity analysis yielded similar results to our primary analysis. Further, in our main analyses, we present average effect estimates of ADF initiation on opioid-related harm. Effect measure modification by treatment history is possible, and future studies that explicitly examine the question of modification of the relationship between ADF initiation and opioid-related harms by treatment history would be valuable contributions to the evidence base.</p><p>There are several additional limitations to consider when interpreting the findings from this study. First, opioid overdose and OUD are notoriously difficult to measure in claims data.<xref rid="ref68" ref-type="bibr"><sup>68</sup></xref><sup>,</sup><xref rid="ref69" ref-type="bibr"><sup>69</sup></xref> Linking death records allowed us to examine fatal opioid overdoses in our study population. Additionally, we conducted 2 sensitivity analyses of OUD outcomes, incorporating MOUD into our outcome definition and excluding OUD outcomes in the first 30&#160;days in the event that these represented prevalent OUD diagnoses rather than incident events, with results consistent with findings from primary analyses. Second, while enrollment requirements and washout periods can exclude eligible patients<xref rid="ref70" ref-type="bibr"><sup>70&#8211;72</sup></xref> and claims data are an imperfect source of historical information about a patient&#8217;s treatment history, we chose to impose specific enrollment and washout requirements because it was important to ensure that we could capture a patient&#8217;s full treatment history with opioid analgesics (since their most recent washout period) when implementing the study design outlined in this article. We believe that treatment history is an important factor in the relationship between ADF use and opioid-related harm, and by ensuring that we were capturing a more complete treatment history, we sought to minimize the risk of measurement error of prior prescribed opioid analgesic exposure. Third, while we used IPTW to control for measured confounding, there remained the potential for unmeasured confounding. Fourth, many patients disenrolled before the end of follow-up or were censored after 30&#160;days without evidence of an ADF or non-ADF ER/LA prescription in the per-protocol analysis. That extended-release opioids are being used for such short durations has not been previously documented. We used IPTCW to account for informative censoring and included a secondary analysis with an ITT approach to evaluate the impact of the per-protocol assumption on our findings, which produced similar results. Fifth, we caution against drawing firm conclusions about the relationship between ADF use and opioid overdose, given that these estimates had low precision. Finally, our data source included privately insured patients in NC and may not be representative of patients with Medicaid, Medicare, or those without insurance or in other regions of the country.</p><p>Even though the current problems with overdose in the United States are more closely linked to illicitly manufactured opioids (eg, street fentanyl), ADFs of novel opioid analgesics, stimulants, and cannabinoids are currently under development by pharmaceutical companies. We humbly suggest that the methods described in this study can provide a starting point for observational studies of real-world impacts of ADFs on the intended patient population.</p></sec><sec id="sec18"><title>Conclusions</title><p>Our study aimed to answer the growing call to improve the methodological approaches in opioid safety research. In this sample of privately insured patients prescribed ER/LA opioids in NC, we used a methodologically rigorous study design to evaluate the relationship between ADFs and opioid-related harms among patients with variable opioid treatment histories and found no relationship between ADF use and opioid overdose. Interestingly, we found that ADF use was associated with a lower risk of OUD early in follow-up, but this relationship did not hold after 6&#160;weeks, suggesting a possible limited short-term benefit from ADFs. These findings add to the expanding body of evidence that there is not a clear long-term reduction in harm from ADFs. Future work will continue to evaluate the implications of design and analytic choices in opioid safety research.</p></sec><sec id="sec19"><title>Acknowledgments</title><p>We are grateful to colleagues at the FDA Office of Surveillance and Epidemiology for conceptual discussions that shaped our thinking on this analysis. We also thank research support staff at UNC who helped make the science possible, specifically Maryalice Nocera and LaMonda Sykes.</p></sec><sec sec-type="supplementary-material" id="sec20"><title>Supplementary material</title><p>
<xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref> is available at the <italic toggle="yes">American Journal of Epidemiology</italic> online.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data" orientation="portrait"><label>Web_Material_kwae252</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="web_material_kwae252.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><sec id="sec21"><title>Funding</title><p>This work was supported by a grant from the US Food and Drug Administration (HHSF223201810183C).</p></sec><sec sec-type="COI-statement" id="sec22"><title>Conflict of interest</title><p>N.D. is a scientific advisor to the nonprofit RADARS System of Denver Health and Hospitals Authority (Colorado), which had no knowledge of or involvement in this research.</p></sec><sec id="sec23"><title>Disclaimer</title><p>This article does not necessarily reflect the views of the US Food and Drug Administration, should not be construed as regulatory guidance, and is the sole responsibility of the authors. The decision to publish was not influenced by the funder (FDA).</p></sec><sec sec-type="data-availability" id="sec24"><title>Data availability</title><p>The insurance claims data and death records used in this study require Data Use Agreements for access.</p></sec><ref-list id="bib1"><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dart</surname> &#160;<given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Surratt</surname> &#160;<given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Cicero</surname> &#160;<given-names>TJ</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Trends in opioid analgesic abuse and mortality in the United States</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2015</year>;<volume>372</volume>(<issue>3</issue>):<fpage>241</fpage>-<lpage>248</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMsa1406143</pub-id><pub-id pub-id-type="pmid">25587948</pub-id></mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Katz</surname> &#160;<given-names>NP</given-names></string-name>, <string-name name-style="western"><surname>Adams</surname> &#160;<given-names>EH</given-names></string-name>, <string-name name-style="western"><surname>Chilcoat</surname> &#160;<given-names>H</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Challenges in the development of prescription opioid abuse-deterrent formulations</article-title>. <source><italic toggle="yes">Clin J Pain</italic></source>. <year>2007</year>;<volume>23</volume>(<issue>8</issue>):<fpage>648</fpage>-<lpage>660</lpage>. <pub-id pub-id-type="doi">10.1097/AJP.0b013e318125c5e8</pub-id><pub-id pub-id-type="pmid">17885342</pub-id></mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gasior</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bond</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Malamut</surname> &#160;<given-names>R</given-names></string-name></person-group>. <article-title>Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations</article-title>. <source><italic toggle="yes">Postgrad Med</italic></source>. <year>2016</year>;<volume>128</volume>(<issue>1</issue>):<fpage>85</fpage>-<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1080/00325481.2016.1120642</pub-id><pub-id pub-id-type="pmid">26566680</pub-id></mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mastropietro</surname> &#160;<given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Omidian</surname> &#160;<given-names>H</given-names></string-name></person-group>. <article-title>Current approaches in tamper-resistant and abuse-deterrent formulations</article-title>. <source><italic toggle="yes">Drug Dev Ind Pharm</italic></source>. <year>2013</year>;<volume>39</volume>(<issue>5</issue>):<fpage>611</fpage>-<lpage>624</lpage>. <pub-id pub-id-type="doi">10.3109/03639045.2012.680468</pub-id><pub-id pub-id-type="pmid">22537282</pub-id></mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Paljarvi</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Strang</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Quinn</surname> &#160;<given-names>PD</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Abuse-deterrent extended-release oxycodone and risk of opioid-related harm</article-title>. <source><italic toggle="yes">Addiction</italic></source>. <year>2021</year>;<volume>116</volume>(<issue>9</issue>):<fpage>2409</fpage>-<lpage>2415</lpage>. <pub-id pub-id-type="doi">10.1111/add.15392</pub-id><pub-id pub-id-type="pmid">33394528</pub-id><pub-id pub-id-type="pmcid">PMC8363193</pub-id></mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baum</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hsu</surname> &#160;<given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Nelson</surname> &#160;<given-names>RC</given-names></string-name></person-group>. <article-title>The impact of the addition of naloxone on the use and abuse of pentazocine</article-title>. <source><italic toggle="yes">Public Health Rep</italic></source>. <year>1987</year>;<volume>102</volume>(<issue>4</issue>):<fpage>426</fpage>-<lpage>429</lpage>.<pub-id pub-id-type="pmid">3112855</pub-id><pub-id pub-id-type="pmcid">PMC1477863</pub-id></mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reed</surname> &#160;<given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Schnoll</surname> &#160;<given-names>SH</given-names></string-name></person-group>. <article-title>Abuse of pentazocine-naloxone combination</article-title>. <source><italic toggle="yes">JAMA</italic></source>. <year>1986</year>;<volume>256</volume>(<issue>18</issue>):<fpage>2562</fpage>-<lpage>2564</lpage>. <pub-id pub-id-type="doi">10.1001/jama.1986.03380180124033</pub-id><pub-id pub-id-type="pmid">3773159</pub-id></mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Poklis</surname> &#160;<given-names>A</given-names></string-name></person-group>. <article-title>Decline in abuse of pentazocine/tripelennamine (T's and blues) associated with the addition of naloxone to pentazocine tablets</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>1984</year>;<volume>14</volume>(<issue>2</issue>):<fpage>135</fpage>-<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1016/0376-8716(84)90039-5</pub-id><pub-id pub-id-type="pmid">6510217</pub-id></mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fudala</surname> &#160;<given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname> &#160;<given-names>RE</given-names></string-name></person-group>. <article-title>Development of opioid formulations with limited diversion and abuse potential</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2006</year>;<volume>83</volume>(<issue>suppl 1</issue>):<fpage>S40</fpage>-<lpage>S47</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2006.01.016</pub-id><pub-id pub-id-type="pmid">16564141</pub-id></mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Katz</surname> &#160;<given-names>N</given-names></string-name></person-group>. <article-title>Abuse-deterrent opioid formulations: are they a pipe dream?</article-title> &#160;<source><italic toggle="yes">Curr Rheumatol Rep</italic></source>. <year>2008</year>;<volume>10</volume>(<issue>1</issue>):<fpage>11</fpage>-<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1007/s11926-008-0003-z</pub-id><pub-id pub-id-type="pmid">18457606</pub-id></mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Broz</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zibbell</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Foote</surname> &#160;<given-names>C</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Multiple injections per injection episode: high-risk injection practice among people who injected pills during the 2015 HIV outbreak in Indiana</article-title>. <source><italic toggle="yes">Int J Drug Policy</italic></source>. <year>2018</year>;<volume>52</volume>:<fpage>97</fpage>-<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugpo.2017.12.003</pub-id><pub-id pub-id-type="pmid">29278838</pub-id><pub-id pub-id-type="pmcid">PMC11337051</pub-id></mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hunt</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yalamanoglu</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tumlin</surname> &#160;<given-names>J</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER</article-title>. <source><italic toggle="yes">Blood</italic></source>. <year>2017</year>;<volume>129</volume>(<issue>7</issue>):<fpage>896</fpage>-<lpage>905</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2016-08-736579</pub-id><pub-id pub-id-type="pmid">27864296</pub-id><pub-id pub-id-type="pmcid">PMC5314814</pub-id></mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mateu-Gelabert</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Guarino</surname> &#160;<given-names>H</given-names></string-name></person-group>. <article-title>The opioid epidemic and injection drug use: MIPIE and health harms related to the injection of prescription opioids</article-title>. <source><italic toggle="yes">Int J Drug Policy</italic></source>. <year>2018</year>;<volume>57</volume>:<fpage>130</fpage>-<lpage>132</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugpo.2018.03.019</pub-id><pub-id pub-id-type="pmid">29627198</pub-id><pub-id pub-id-type="pmcid">PMC6062003</pub-id></mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Katz</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Dart</surname> &#160;<given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Bailey</surname> &#160;<given-names>E</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions</article-title>. <source><italic toggle="yes">Am J Drug Alcohol Abuse</italic></source>. <year>2011</year>;<volume>37</volume>(<issue>4</issue>):<fpage>205</fpage>-<lpage>217</lpage>. <pub-id pub-id-type="doi">10.3109/00952990.2011.569623</pub-id><pub-id pub-id-type="pmid">21517709</pub-id></mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="book">U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). <source>Abuse-Deterrent Opioids&#8212;Evaluation and Labeling</source>. <publisher-name>Guidance for Industry</publisher-name>; <year>2015</year>.</mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="book">U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). <source>General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products</source>. <publisher-name>Guidance for Industry</publisher-name>; <year>2017</year>.</mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Severtson</surname> &#160;<given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Ellis</surname> &#160;<given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Kurtz</surname> &#160;<given-names>SP</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2016</year>;<volume>168</volume>:<fpage>219</fpage>-<lpage>229</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2016.09.018</pub-id><pub-id pub-id-type="pmid">27716575</pub-id></mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Coplan</surname> &#160;<given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Chilcoat</surname> &#160;<given-names>HD</given-names></string-name>, <string-name name-style="western"><surname>Butler</surname> &#160;<given-names>SF</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting</article-title>. <source><italic toggle="yes">Clin Pharmacol Ther</italic></source>. <year>2016</year>;<volume>100</volume>(<issue>3</issue>):<fpage>275</fpage>-<lpage>286</lpage>. <pub-id pub-id-type="doi">10.1002/cpt.390</pub-id><pub-id pub-id-type="pmid">27170195</pub-id><pub-id pub-id-type="pmcid">PMC5102571</pub-id></mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jewell</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Black</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ellis</surname> &#160;<given-names>M</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>A cross-sectional study of tampering in Xtampza ER, an abuse-deterrent formulation of an extended-release opioid, in a treatment center population</article-title>. <source><italic toggle="yes">Clin Drug Investig</italic></source>. <year>2023</year>;<volume>43</volume>(<issue>3</issue>):<fpage>197</fpage>-<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1007/s40261-023-01248-9</pub-id><pub-id pub-id-type="pmcid">PMC10049928</pub-id><pub-id pub-id-type="pmid">36859697</pub-id></mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cassidy</surname> &#160;<given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>DasMahapatra</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Black</surname> &#160;<given-names>RA</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation</article-title>. <source><italic toggle="yes">Pain Med</italic></source>. <year>2014</year>;<volume>15</volume>(<issue>3</issue>):<fpage>440</fpage>-<lpage>451</lpage>. <pub-id pub-id-type="doi">10.1111/pme.12295</pub-id><pub-id pub-id-type="pmid">24330279</pub-id></mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wolff</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dowd</surname> &#160;<given-names>WN</given-names></string-name>, <string-name name-style="western"><surname>Ali</surname> &#160;<given-names>MM</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>The impact of the abuse-deterrent reformulation of extended-release OxyContin on prescription pain reliever misuse and heroin initiation</article-title>. <source><italic toggle="yes">Addict Behav</italic></source>. <year>2020</year>;<volume>105</volume>:<elocation-id>106268</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.addbeh.2019.106268</pub-id><pub-id pub-id-type="pmid">32036188</pub-id></mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alpert</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Powell</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Pacula</surname> &#160;<given-names>RL</given-names></string-name></person-group>. <article-title>Supply-side drug policy in the presence of substitutes: evidence from the introduction of abuse-deterrent opioids</article-title>. <source><italic toggle="yes">Am Econ J Econ Policy</italic></source>. <year>2018</year>;<volume>10</volume>(<issue>4</issue>):<fpage>1</fpage>-<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1257/pol.20170082</pub-id><pub-id pub-id-type="pmid">34326924</pub-id><pub-id pub-id-type="pmcid">PMC8317673</pub-id></mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nolan</surname> &#160;<given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Harocopos</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Allen</surname> &#160;<given-names>B</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Reformulation of oxycodone 80&#160;mg to prevent misuse: a cohort study assessing the impact of a supply-side intervention</article-title>. <source><italic toggle="yes">Int J Drug Policy</italic></source>. <year>2020</year>;<volume>83</volume>:<elocation-id>102848</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.drugpo.2020.102848</pub-id><pub-id pub-id-type="pmid">32645583</pub-id></mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>DiNardi</surname> &#160;<given-names>M</given-names></string-name></person-group>. <article-title>The release of abuse-deterrent OxyContin and adolescent heroin use</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2021</year>;<volume>229</volume>(<issue>pt B</issue>):<elocation-id>109114</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2021.109114</pub-id><pub-id pub-id-type="pmid">34638038</pub-id></mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rodriguez</surname> &#160;<given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Dailey Govoni</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Rajagopal</surname> &#160;<given-names>V</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Evaluating the effectiveness of reformulated extended-release oxycodone with abuse-deterrent properties on reducing non-oral abuse among individuals assessed for substance abuse treatment with the Addiction Severity Index-Multimedia Version (ASI-MV)</article-title>. <source><italic toggle="yes">Curr Med Res Opin</italic></source>. <year>2023</year>;<volume>39</volume>(<issue>4</issue>):<fpage>579</fpage>-<lpage>587</lpage>. <pub-id pub-id-type="doi">10.1080/03007995.2023.2178080</pub-id><pub-id pub-id-type="pmid">36762423</pub-id></mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Havens</surname> &#160;<given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Leukefeld</surname> &#160;<given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>DeVeaugh-Geiss</surname> &#160;<given-names>AM</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2014</year>;<volume>139</volume>:<fpage>9</fpage>-<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2014.02.018</pub-id><pub-id pub-id-type="pmid">24721614</pub-id></mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hwang</surname> &#160;<given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname> &#160;<given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Alexander</surname> &#160;<given-names>GC</given-names></string-name></person-group>. <article-title>Impact of abuse-deterrent OxyContin on prescription opioid utilization</article-title>. <source><italic toggle="yes">Pharmacoepidemiol Drug Saf</italic></source>. <year>2015</year>;<volume>24</volume>(<issue>2</issue>):<fpage>197</fpage>-<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1002/pds.3723</pub-id><pub-id pub-id-type="pmid">25393216</pub-id></mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Buer</surname> &#160;<given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Havens</surname> &#160;<given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Leukefeld</surname> &#160;<given-names>C</given-names></string-name></person-group>. <article-title>Does the new formulation of OxyContin(R) deter misuse? A qualitative analysis</article-title>. <source><italic toggle="yes">Subst Use Misuse</italic></source>. <year>2014</year>;<volume>49</volume>(<issue>6</issue>):<fpage>770</fpage>-<lpage>774</lpage>. <pub-id pub-id-type="doi">10.3109/10826084.2013.866963</pub-id><pub-id pub-id-type="pmid">24354546</pub-id></mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chilcoat</surname> &#160;<given-names>HD</given-names></string-name>, <string-name name-style="western"><surname>Coplan</surname> &#160;<given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Harikrishnan</surname> &#160;<given-names>V</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin)</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2016</year>;<volume>165</volume>:<fpage>221</fpage>-<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2016.06.009</pub-id><pub-id pub-id-type="pmid">27372220</pub-id></mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Coplan</surname> &#160;<given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Kale</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sandstrom</surname> &#160;<given-names>L</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics</article-title>. <source><italic toggle="yes">Pharmacoepidemiol Drug Saf</italic></source>. <year>2013</year>;<volume>22</volume>(<issue>12</issue>):<fpage>1274</fpage>-<lpage>1282</lpage>. <pub-id pub-id-type="doi">10.1002/pds.3522</pub-id><pub-id pub-id-type="pmid">24123484</pub-id><pub-id pub-id-type="pmcid">PMC4283730</pub-id></mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dasgupta</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname> &#160;<given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Nocera</surname> &#160;<given-names>M</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Abuse-deterrent opioids: a survey of physician beliefs, behaviors, and psychology</article-title>. <source><italic toggle="yes">Pain Ther</italic></source>. <year>2022</year>;<volume>11</volume>(<issue>1</issue>):<fpage>133</fpage>-<lpage>151</lpage>. <pub-id pub-id-type="doi">10.1007/s40122-021-00343-z</pub-id><pub-id pub-id-type="pmid">34870790</pub-id><pub-id pub-id-type="pmcid">PMC8861217</pub-id></mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brown</surname> &#160;<given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Oh</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname> &#160;<given-names>Y</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Variation in abuse-deterrent formulation opioid prescribing in California, Florida, and Kentucky in 2018</article-title>. <source><italic toggle="yes">J Rural Health</italic></source>. <year>2021</year>;<volume>37</volume>(<issue>1</issue>):<fpage>23</fpage>-<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1111/jrh.12496</pub-id><pub-id pub-id-type="pmid">32686223</pub-id></mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Oyler</surname> &#160;<given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Slavova</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname> &#160;<given-names>JR</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Kentucky pharmacists' experiences in dispensing abuse-deterrent opioid analgesics</article-title>. <source><italic toggle="yes">J Am Pharm Assoc</italic> (2003)</source>. <year>2022</year>;<volume>62</volume>(<issue>6</issue>):<fpage>1836</fpage>-<lpage>1842</lpage>. <pub-id pub-id-type="doi">10.1016/j.japh.2022.07.017</pub-id><pub-id pub-id-type="pmid">36031547</pub-id></mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Degenhardt</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Larance</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bruno</surname> &#160;<given-names>R</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol</article-title>. <source><italic toggle="yes">Addiction</italic></source>. <year>2015</year>;<volume>110</volume>(<issue>2</issue>):<fpage>226</fpage>-<lpage>237</lpage>. <pub-id pub-id-type="doi">10.1111/add.12746</pub-id><pub-id pub-id-type="pmid">25358480</pub-id></mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Larance</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Dobbins</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Peacock</surname> &#160;<given-names>A</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study</article-title>. <source><italic toggle="yes">Lancet Psychiatry</italic></source>. <year>2018</year>;<volume>5</volume>(<issue>2</issue>):<fpage>155</fpage>-<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1016/S2215-0366(18)30003-8</pub-id><pub-id pub-id-type="pmid">29336948</pub-id></mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Degenhardt</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bruno</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ali</surname> &#160;<given-names>R</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>The introduction of a potentially abuse deterrent oxycodone formulation: early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2015</year>;<volume>151</volume>:<fpage>56</fpage>-<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2015.02.038</pub-id><pub-id pub-id-type="pmid">25910850</pub-id></mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Campbell</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bruno</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lintzeris</surname> &#160;<given-names>N</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic noncancer pain: do different measures identify the same patients?</article-title> &#160;<source><italic toggle="yes">Pain</italic></source>. <year>2016</year>;<volume>157</volume>(<issue>7</issue>):<fpage>1489</fpage>-<lpage>1498</lpage>. <pub-id pub-id-type="doi">10.1097/j.pain.0000000000000548</pub-id><pub-id pub-id-type="pmid">26963848</pub-id></mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cicero</surname> &#160;<given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Mendoza</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cattaneo</surname> &#160;<given-names>M</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients</article-title>. <source><italic toggle="yes">Postgrad Med</italic></source>. <year>2019</year>;<volume>131</volume>(<issue>3</issue>):<fpage>225</fpage>-<lpage>229</lpage>. <pub-id pub-id-type="doi">10.1080/00325481.2019.1585688</pub-id><pub-id pub-id-type="pmid">30794760</pub-id></mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Taber</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bond</surname> &#160;<given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname> &#160;<given-names>X</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Real-world utilization of once-daily extended-release abuse deterrent formulation of hydrocodone: a comparison with the pre-approval randomized clinical trials</article-title>. <source><italic toggle="yes">J Pain Res</italic></source>. <year>2017</year>;<volume>10</volume>:<fpage>1741</fpage>-<lpage>1746</lpage>. <pub-id pub-id-type="doi">10.2147/JPR.S140990</pub-id><pub-id pub-id-type="pmid">28794653</pub-id><pub-id pub-id-type="pmcid">PMC5536138</pub-id></mixed-citation></ref><ref id="ref40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Beachler</surname> &#160;<given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Garg</surname> &#160;<given-names>R</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>An evaluation of the effect of the OxyContin reformulation on unintentional fatal and nonfatal overdose</article-title>. <source><italic toggle="yes">Clin J Pain</italic></source>. <year>2022</year>;<volume>38</volume>(<issue>6</issue>):<fpage>396</fpage>-<lpage>404</lpage>. <pub-id pub-id-type="doi">10.1097/AJP.0000000000001034</pub-id><pub-id pub-id-type="pmid">35356897</pub-id><pub-id pub-id-type="pmcid">PMC9076252</pub-id></mixed-citation></ref><ref id="ref41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Turk</surname> &#160;<given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>O'Connor</surname> &#160;<given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Dworkin</surname> &#160;<given-names>RH</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations</article-title>. <source><italic toggle="yes">Pain</italic></source>. <year>2012</year>;<volume>153</volume>(<issue>10</issue>):<fpage>1997</fpage>-<lpage>2008</lpage>. <pub-id pub-id-type="doi">10.1016/j.pain.2012.05.029</pub-id><pub-id pub-id-type="pmid">22770841</pub-id><pub-id pub-id-type="pmcid">PMC3617214</pub-id></mixed-citation></ref><ref id="ref42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Peacock</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Larance</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bruno</surname> &#160;<given-names>R</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting</article-title>. <source><italic toggle="yes">Addiction</italic></source>. <year>2019</year>;<volume>114</volume>(<issue>3</issue>):<fpage>389</fpage>-<lpage>399</lpage>. <pub-id pub-id-type="doi">10.1111/add.14380</pub-id><pub-id pub-id-type="pmid">29989247</pub-id><pub-id pub-id-type="pmcid">PMC6599581</pub-id></mixed-citation></ref><ref id="ref43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Walker</surname> &#160;<given-names>AM</given-names></string-name></person-group>. <article-title>Confounding by indication</article-title>. <source><italic toggle="yes">Epidemiology</italic></source>. <year>1996</year>;<volume>7</volume>(<issue>4</issue>):<fpage>335</fpage>-<lpage>336</lpage>.<pub-id pub-id-type="pmid">8793355</pub-id></mixed-citation></ref><ref id="ref44"><label>44.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>US Food and Drug Administration</collab></person-group>. <italic toggle="yes">Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting: A Scientific Discussion of Present and Future Capabilities</italic>. FDA; <year>2017</year>.</mixed-citation></ref><ref id="ref45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Suissa</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Moodie</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Dell'Aniello</surname> &#160;<given-names>S</given-names></string-name></person-group>. <article-title>Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores</article-title>. <source><italic toggle="yes">Pharmacoepidemiol Drug Saf</italic></source>. <year>2017</year>;<volume>26</volume>(<issue>4</issue>):<fpage>459</fpage>-<lpage>468</lpage>. <pub-id pub-id-type="doi">10.1002/pds.4107</pub-id><pub-id pub-id-type="pmid">27610604</pub-id></mixed-citation></ref><ref id="ref46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Webster-Clark</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ross</surname> &#160;<given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Lund</surname> &#160;<given-names>JL</given-names></string-name></person-group>. <article-title>Initiator types and the causal question of the prevalent new-user design: a simulation study</article-title>. <source><italic toggle="yes">Am J Epidemiol</italic></source>. <year>2021</year>;<volume>190</volume>(<issue>7</issue>):<fpage>1341</fpage>-<lpage>1348</lpage>. <pub-id pub-id-type="doi">10.1093/aje/kwaa283</pub-id><pub-id pub-id-type="pmid">33350433</pub-id><pub-id pub-id-type="pmcid">PMC8245871</pub-id></mixed-citation></ref><ref id="ref47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lund</surname> &#160;<given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Richardson</surname> &#160;<given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>St&#252;rmer</surname> &#160;<given-names>T</given-names></string-name></person-group>. <article-title>The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application</article-title>. <source><italic toggle="yes">Curr Epidemiol Rep</italic></source>. <year>2015</year>;<volume>2</volume>(<issue>4</issue>):<fpage>221</fpage>-<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1007/s40471-015-0053-5</pub-id><pub-id pub-id-type="pmid">26954351</pub-id><pub-id pub-id-type="pmcid">PMC4778958</pub-id></mixed-citation></ref><ref id="ref48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ray</surname> &#160;<given-names>WA</given-names></string-name></person-group>. <article-title>Evaluating medication effects outside of clinical trials: new-user designs</article-title>. <source><italic toggle="yes">Am J Epidemiol</italic></source>. <year>2003</year>;<volume>158</volume>(<issue>9</issue>):<fpage>915</fpage>-<lpage>920</lpage>. <pub-id pub-id-type="doi">10.1093/aje/kwg231</pub-id><pub-id pub-id-type="pmid">14585769</pub-id></mixed-citation></ref><ref id="ref49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cole</surname> &#160;<given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Hudgens</surname> &#160;<given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Brookhart</surname> &#160;<given-names>MA</given-names></string-name></person-group>, <comment>Westreich D</comment>. Risk. <source>Am J Epidemiol</source> &#160;<year>2015</year>;<volume>181</volume>(<issue>4</issue>):<fpage>246</fpage>-<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1093/aje/kwv001</pub-id><pub-id pub-id-type="pmid">25660080</pub-id><pub-id pub-id-type="pmcid">PMC4325680</pub-id></mixed-citation></ref><ref id="ref50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cole</surname> &#160;<given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Lau</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Eron</surname> &#160;<given-names>JJ</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Estimation of the standardized risk difference and ratio in a competing risks framework: application to injection drug use and progression to AIDS after initiation of antiretroviral therapy</article-title>. <source><italic toggle="yes">Am J Epidemiol</italic></source>. <year>2015</year>;<volume>181</volume>(<issue>4</issue>):<fpage>238</fpage>-<lpage>245</lpage>. <pub-id pub-id-type="doi">10.1093/aje/kwu122</pub-id><pub-id pub-id-type="pmid">24966220</pub-id><pub-id pub-id-type="pmcid">PMC4325676</pub-id></mixed-citation></ref><ref id="ref51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hernan</surname> &#160;<given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Hernandez-Diaz</surname> &#160;<given-names>S</given-names></string-name></person-group>. <article-title>Beyond the intention-to-treat in comparative effectiveness research</article-title>. <source><italic toggle="yes">Clin Trials</italic></source>. <year>2012</year>;<volume>9</volume>(<issue>1</issue>):<fpage>48</fpage>-<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1177/1740774511420743</pub-id><pub-id pub-id-type="pmid">21948059</pub-id><pub-id pub-id-type="pmcid">PMC3731071</pub-id></mixed-citation></ref><ref id="ref52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moore</surname> &#160;<given-names>BJJ</given-names></string-name>, <string-name name-style="western"><surname>White</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Washington</surname> &#160;<given-names>R</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Identifying increased risk of readmission and in-hospital mortality using hospital administrative data: The AHRQ Elixhauser Comorbidity Index</article-title>. <source>Med Care.</source> &#160;<year>2017</year>;<volume>55</volume>(<issue>7</issue>):<fpage>698</fpage>-<lpage>705</lpage>. <pub-id pub-id-type="doi">10.1097/MLR.0000000000000735</pub-id><pub-id pub-id-type="pmid">28498196</pub-id></mixed-citation></ref><ref id="ref53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dasgupta</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Bae</surname> &#160;<given-names>J</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Inches, centimeters, and yards: overlooked definition choices inhibit interpretation of morphine equivalence</article-title>. <source><italic toggle="yes">Clin J Pain</italic></source>. <year>2021</year>;<volume>37</volume>(<issue>8</issue>):<fpage>565</fpage>-<lpage>574</lpage>. <pub-id pub-id-type="doi">10.1097/AJP.0000000000000948</pub-id><pub-id pub-id-type="pmid">34116543</pub-id><pub-id pub-id-type="pmcid">PMC8270512</pub-id></mixed-citation></ref><ref id="ref54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Austin</surname> &#160;<given-names>PC</given-names></string-name></person-group>. <article-title>Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples</article-title>. <source><italic toggle="yes">Stat Med</italic></source>. <year>2009</year>;<volume>28</volume>(<issue>25</issue>):<fpage>3083</fpage>-<lpage>3107</lpage>. <pub-id pub-id-type="doi">10.1002/sim.3697</pub-id><pub-id pub-id-type="pmid">19757444</pub-id><pub-id pub-id-type="pmcid">PMC3472075</pub-id></mixed-citation></ref><ref id="ref55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cole</surname> &#160;<given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Hern&#225;n</surname> &#160;<given-names>MA</given-names></string-name></person-group>. <article-title>Constructing inverse probability weights for marginal structural models</article-title>. <source><italic toggle="yes">Am J Epidemiol</italic></source>. <year>2008</year>;<volume>168</volume>(<issue>6</issue>):<fpage>656</fpage>-<lpage>664</lpage>. <pub-id pub-id-type="doi">10.1093/aje/kwn164</pub-id><pub-id pub-id-type="pmid">18682488</pub-id><pub-id pub-id-type="pmcid">PMC2732954</pub-id></mixed-citation></ref><ref id="ref56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fine</surname> &#160;<given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Gray</surname> &#160;<given-names>RJ</given-names></string-name></person-group>. <article-title>A proportional hazards model for the subdistribution of a competing risk</article-title>. <source><italic toggle="yes">J Am Stat Assoc</italic></source>. <year>1999</year>;<volume>94</volume>(<issue>446</issue>):<fpage>496</fpage>-<lpage>509</lpage>. <pub-id pub-id-type="doi">10.1080/01621459.1999.10474144</pub-id></mixed-citation></ref><ref id="ref57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mumford</surname> &#160;<given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Schisterman</surname> &#160;<given-names>EF</given-names></string-name>, <string-name name-style="western"><surname>Cole</surname> &#160;<given-names>SR</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Time at risk and intention-to-treat analyses: parallels and implications for inference</article-title>. <source><italic toggle="yes">Epidemiology</italic></source>. <year>2015</year>;<volume>26</volume>(<issue>1</issue>):<fpage>112</fpage>-<lpage>118</lpage>. <pub-id pub-id-type="doi">10.1097/EDE.0000000000000188</pub-id><pub-id pub-id-type="pmid">25275571</pub-id><pub-id pub-id-type="pmcid">PMC6191842</pub-id></mixed-citation></ref><ref id="ref58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ranapurwala</surname> &#160;<given-names>SI</given-names></string-name>, <string-name name-style="western"><surname>Naumann</surname> &#160;<given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Austin</surname> &#160;<given-names>AE</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Methodologic limitations of prescription opioid safety research and recommendations for improving the evidence base</article-title>. <source><italic toggle="yes">Pharmacoepidemiol Drug Saf</italic></source>. <year>2019</year>;<volume>28</volume>(<issue>1</issue>):<fpage>4</fpage>-<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1002/pds.4564</pub-id><pub-id pub-id-type="pmid">29862602</pub-id></mixed-citation></ref><ref id="ref59"><label>59.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>R Core Team</collab></person-group>. <source>R: A Language and Environment for Statistical Computing</source>. <publisher-name>R Foundation for Statistical Computing</publisher-name>; <year>2019</year>. Accessed May 2019.</mixed-citation></ref><ref id="ref60"><label>60.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>US Food and Drug Administration</collab></person-group>. FDA analysis of long-term trends in prescription opioid analgesic products: quantity, sales, and Price trends. <year>March 1, 2018</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/111695/download" ext-link-type="uri">https://www.fda.gov/media/111695/download</ext-link></mixed-citation></ref><ref id="ref61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Litman</surname> &#160;<given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Pagan</surname> &#160;<given-names>OH</given-names></string-name>, <string-name name-style="western"><surname>Cicero</surname> &#160;<given-names>TJ</given-names></string-name></person-group>. <article-title>Abuse-deterrent opioid formulations</article-title>. <source><italic toggle="yes">Anesthesiology</italic></source>. <year>2018</year>;<volume>128</volume>(<issue>5</issue>):<fpage>1015</fpage>-<lpage>1026</lpage>. <pub-id pub-id-type="doi">10.1097/ALN.0000000000002031</pub-id><pub-id pub-id-type="pmid">29252508</pub-id></mixed-citation></ref><ref id="ref62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cicero</surname> &#160;<given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Ellis</surname> &#160;<given-names>MS</given-names></string-name></person-group>. <article-title>Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin</article-title>. <source><italic toggle="yes">JAMA Psychiatry</italic></source>. <year>2015</year>;<volume>72</volume>(<issue>5</issue>):<fpage>424</fpage>-<lpage>430</lpage>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.3043</pub-id><pub-id pub-id-type="pmid">25760692</pub-id></mixed-citation></ref><ref id="ref63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Severtson</surname> &#160;<given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Bartelson</surname> &#160;<given-names>BB</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname> &#160;<given-names>JM</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010</article-title>. <source><italic toggle="yes">J Pain</italic></source>. <year>2013</year>;<volume>14</volume>(<issue>10</issue>):<fpage>1122</fpage>-<lpage>1130</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpain.2013.04.011</pub-id><pub-id pub-id-type="pmid">23816949</pub-id></mixed-citation></ref><ref id="ref64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sessler</surname> &#160;<given-names>NE</given-names></string-name>, <string-name name-style="western"><surname>Downing</surname> &#160;<given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Kale</surname> &#160;<given-names>H</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation</article-title>. <source><italic toggle="yes">Pharmacoepidemiol Drug Saf</italic></source>. <year>2014</year>;<volume>23</volume>(<issue>12</issue>):<fpage>1238</fpage>-<lpage>1246</lpage>. <pub-id pub-id-type="doi">10.1002/pds.3658</pub-id><pub-id pub-id-type="pmid">24916486</pub-id><pub-id pub-id-type="pmcid">PMC4282788</pub-id></mixed-citation></ref><ref id="ref65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Butler</surname> &#160;<given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Cassidy</surname> &#160;<given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Chilcoat</surname> &#160;<given-names>H</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment</article-title>. <source><italic toggle="yes">J Pain</italic></source>. <year>2013</year>;<volume>14</volume>(<issue>4</issue>):<fpage>351</fpage>-<lpage>358</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpain.2012.08.008</pub-id><pub-id pub-id-type="pmid">23127293</pub-id></mixed-citation></ref><ref id="ref66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dasgupta</surname> &#160;<given-names>N</given-names></string-name></person-group>. <article-title>Commentary on Paljarvi et&#160;al: can harder-to-crush oxycodone prevent overdose?</article-title> &#160;<source><italic toggle="yes">Addiction</italic></source>. <year>2021</year>;<volume>116</volume>(<issue>9</issue>):<fpage>2416</fpage>-<lpage>2417</lpage>. <pub-id pub-id-type="doi">10.1111/add.15617</pub-id><pub-id pub-id-type="pmid">34263500</pub-id></mixed-citation></ref><ref id="ref67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>By</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>McAninch</surname> &#160;<given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Keeton</surname> &#160;<given-names>SL</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Important statistical considerations in the evaluation of post-market studies to assess whether opioids with abuse-deterrent properties result in reduced abuse in the community</article-title>. <source><italic toggle="yes">Pharmacoepidemiol Drug Saf</italic></source>. <year>2018</year>;<volume>27</volume>(<issue>5</issue>):<fpage>473</fpage>-<lpage>478</lpage>. <pub-id pub-id-type="doi">10.1002/pds.4287</pub-id><pub-id pub-id-type="pmid">28833803</pub-id></mixed-citation></ref><ref id="ref68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rowe</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Vittinghoff</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Santos</surname> &#160;<given-names>GM</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Performance measures of diagnostic codes for detecting opioid overdose in the emergency department</article-title>. <source><italic toggle="yes">Acad Emerg Med</italic></source>. <year>2017</year>;<volume>24</volume>(<issue>4</issue>):<fpage>475</fpage>-<lpage>483</lpage>. <pub-id pub-id-type="doi">10.1111/acem.13121</pub-id><pub-id pub-id-type="pmid">27763703</pub-id></mixed-citation></ref><ref id="ref69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ranapurwala</surname> &#160;<given-names>SI</given-names></string-name>, <string-name name-style="western"><surname>Alam</surname> &#160;<given-names>IZ</given-names></string-name>, <string-name name-style="western"><surname>Pence</surname> &#160;<given-names>BW</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Development and validation of an electronic health records-based opioid use disorder algorithm by expert clinical adjudication among patients with prescribed opioids</article-title>. <source><italic toggle="yes">Pharmacoepidemiol Drug Saf</italic></source>. <year>2023</year>;<volume>32</volume>(<issue>5</issue>):<fpage>577</fpage>-<lpage>585</lpage>. <pub-id pub-id-type="doi">10.1002/pds.5591</pub-id><pub-id pub-id-type="pmid">36585827</pub-id><pub-id pub-id-type="pmcid">PMC10073250</pub-id></mixed-citation></ref><ref id="ref70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Conover</surname> &#160;<given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Sturmer</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Poole</surname> &#160;<given-names>C</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Classifying medical histories in US Medicare beneficiaries using fixed vs all-available look-back approaches</article-title>. <source><italic toggle="yes">Pharmacoepidemiol Drug Saf</italic></source>. <year>2018</year>;<volume>27</volume>(<issue>7</issue>):<fpage>771</fpage>-<lpage>780</lpage>. <pub-id pub-id-type="doi">10.1002/pds.4435</pub-id><pub-id pub-id-type="pmid">29655187</pub-id><pub-id pub-id-type="pmcid">PMC6417795</pub-id></mixed-citation></ref><ref id="ref71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Connolly</surname> &#160;<given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Schneeweiss</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Glynn</surname> &#160;<given-names>RJ</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Quantifying bias reduction with fixed-duration versus all-available covariate assessment periods</article-title>. <source><italic toggle="yes">Pharmacoepidemiol Drug Saf</italic></source>. <year>2019</year>;<volume>28</volume>(<issue>5</issue>):<fpage>665</fpage>-<lpage>670</lpage>. <pub-id pub-id-type="doi">10.1002/pds.4729</pub-id><pub-id pub-id-type="pmid">30786103</pub-id></mixed-citation></ref><ref id="ref72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brunelli</surname> &#160;<given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Gagne</surname> &#160;<given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Huybrechts</surname> &#160;<given-names>KF</given-names></string-name>, <etal>et&#160;al.</etal></person-group> &#160;<article-title>Estimation using all available covariate information versus a fixed look-back window for dichotomous covariates</article-title>. <source><italic toggle="yes">Pharmacoepidemiol Drug Saf</italic></source>. <year>2013</year>;<volume>22</volume>(<issue>5</issue>):<fpage>542</fpage>-<lpage>550</lpage>. <pub-id pub-id-type="doi">10.1002/pds.3434</pub-id><pub-id pub-id-type="pmid">23526818</pub-id><pub-id pub-id-type="pmcid">PMC3653131</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>